View Older Stories View More Recent Stories

Dec 9, 2021 08:00AM Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
Dec 3, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 30, 2021 08:33AM ATARA Biotherapeutics (ATRA) Announces EMA Validates MAA for Tabelecleucel for Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Nov 30, 2021 08:30AM European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproli
Nov 8, 2021 04:01PM Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
Nov 5, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2021 09:30AM Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
Nov 4, 2021 07:30AM Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
Oct 28, 2021 04:01PM Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
Oct 13, 2021 07:30AM Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
Oct 4, 2021 07:36AM ATARA Biotherapeutics (ATRA) and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel
Oct 4, 2021 07:30AM Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
Oct 1, 2021 06:14PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sep 29, 2021 06:06AM ATARA Biotherapeutics (ATRA) to Present Phase 1 Update of ATA188 in MS at ECTRIMS 2021
Sep 29, 2021 03:30AM Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
Sep 27, 2021 08:32AM ATARA Biotherapeutics (ATRA) Announces EMA Grants Accelerated Assessment of tab-cel for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Sep 27, 2021 08:30AM European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Sep 3, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sep 2, 2021 08:30AM Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
Aug 9, 2021 04:03PM ATARA Biotherapeutics (ATRA) Appoints Ameet Mallik to its Board
Aug 9, 2021 04:02PM Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
Aug 9, 2021 04:01PM Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
Aug 2, 2021 06:00PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 2, 2021 08:30AM Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
Jul 2, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jul 1, 2021 04:30PM Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
Jun 7, 2021 10:31AM ATARA Biotherapeutics (ATRA) Presents Positive Tab-cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 202
Jun 7, 2021 10:30AM Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Vir
Jun 4, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 14, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 13, 2021 04:01PM Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
May 10, 2021 08:30AM Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
May 7, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 4, 2021 04:01PM Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
Apr 27, 2021 05:51PM Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
Apr 2, 2021 04:35PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mar 14, 2021 04:00PM Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at Th
Mar 9, 2021 04:01PM Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference
Mar 5, 2021 04:01PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mar 1, 2021 04:05PM Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
Feb 18, 2021 04:01PM Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
Feb 8, 2021 09:07AM ATARA Biotherapeutics (ATRA) Presents Key Data for Advancing the Development of Tab-cel and ATA188 at 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Feb 8, 2021 09:00AM Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Jan 19, 2021 04:14PM Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Jan 10, 2021 04:06PM Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
Jan 6, 2021 08:30AM Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 4, 2021 07:34AM ATARA Biotherapeutics (ATRA) Provides Regulatory Update for Tab-Cel for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Jan 4, 2021 07:30AM Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Dec 7, 2020 07:00AM Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
Dec 7, 2020 06:25AM Bayer and Atara Biotherapeutics (ATRA) Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
View More Recent Stories View Older Stories